甘李药业：GZR4临床成果发表，指标改善优于德谷胰岛素

【甘李药业创新药临床成果发表，指标改善优于竞品】 12月26日消息，甘李药业自主研发的1类创新药胰岛素周制剂GZR4注射液，在中国完成的一项Ib期临床研究成果，正式发表于内分泌领域期刊《Diabetes Research and Clinical ...
China Economic Net

Chinese-Made Intravenous Immunoglobulin (pH4) Approved for Sale in Pakistan

BEIJING, Dec. 25 (China Economic Net) - Guangdong Shuanglin Bio-pharmacy Co., Ltd., a subsidiary of PLBIO, has secured regulatory approval from Pakistan for its Intravenous Immunoglobulin (pH4), a key ...